Contineum Therapeutics CSO Disposes of 4,170 Shares Ahead of Earnings; Company Pursues Upsized Offering
Contineum Therapeutics Chief Scientific Officer Lorrain Daniel S. sold 4,170 shares of Class A common stock on March 2, 2026, under a pre-arranged 10b5-1 trading plan. The transaction occurred as the company's shares traded near a 52-week high and following clinical trial results that prompted an analyst downgrade. Separately, Contineum priced an u…